Navigation Links
Overweight and obese patients less likely to achieve remission in early RA
Date:6/14/2013

Madrid, Spain, 14 June 2013: A new study presented today at EULAR 2013, the Annual Congress of the European League Against Rheumatism, shows that overweight and obese patients are less likely to achieve successful remission in early rheumatoid arthritis (ERA) compared to those of normal weight.

Obese and overweight ERA subjects required 2.4 times more anti-TNF therapy throughout the study than normal weight participants without achieving similar remission outcomes.

RA is a chronic, inflammatory autoimmune disease affecting approximately 1 in 100 people worldwide. RA can cause pain, stiffness, progressive joint destruction and deformity, and reduce physical function, workability, quality of life and life expectancy. At least 50% of RA patients in developed countries are unable to hold down a full-time job within 10 years of onset.2

Obesity continues to remain one of the greatest public health challenges of the 21st century; numbers of those affected rise each year, with the disease now causing 10󈝹% of deaths in Europe.3

"Obesity and rheumatoid arthritis are both on the rise, with devastating effects on individuals and society as a whole. These data reinforce the link between obesity and inflammation, and establish that BMI is one of the few modifiable variables influencing the major outcomes in RA," said Elisa Gremese, Division of Rheumatology, Institute of Rheumatology and Affine Sciences, Catholic University of the Sacred Heart, Rome. "There is an urgent need to address the issues of overweight and obesity to improve patients' chance of successful remission."

346 ERA patients with symptom duration <12 months were categorized into one of three BMI classes (normal weight, overweight and obese) and treated according to a treat-to-target strategy aimed at remission. The strategy included strict follow-up visits, treatment with methotrexate up to 25mg/week+steroids, and combination with a TNF blocker if at least a good response according to EULAR criteria* was not obtained.

Data demonstrate that overweight and obese patients reached a lower rate of remission, both with DAS and CDAI criteria, at 6 and 12 month follow-up visits. A higher percentage of obese and overweight ERA patients were under anti-TNF treatment after 12 months of follow-up compared to normal weight.


'/>"/>

Contact: EULAR Press Office
eularpressoffice@cohnwolfe.com
44-020-733-15364
European League Against Rheumatism
Source:Eurekalert

Related medicine news :

1. Obese patients trust diet advice from overweight physicians more than normal-weight physicians
2. Study Finds Overweight Young Males Have a Greater Risk of Not Surviving Until Age 55, Making Weight Loss Supplements Like Prescopodene Helpful With Increasing Longevity
3. Study: Physicians less likely to bond with overweight patients
4. Overweight While Younger Ups Kidney Risk Later
5. Overweight Cops in Sydney Ordered to Trim Down
6. South Jersey Health and Body Explains the Dangers of Diabetes and What You Must Know if You are Overweight
7. Soccer Kicks Up Activity Level of Overweight Kids: Study
8. Allergy Rescue Shots May Work Better in Lower Thigh of Overweight Kids
9. Poll: Many Americans Dont See Their Kids as Overweight
10. Could Being a Little Overweight Help You Live Longer?
11. Overweight Teens Report High Rates of Bullying, Teasing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/5/2016)... Seattle, WA (PRWEB) , ... May 05, 2016 ... ... one ranking for overall select performance in the industry’s gold standard KLAS ... Expertise? The Epic Consulting report assessed organizations that specialize in consulting services ...
(Date:5/5/2016)... ... May 05, 2016 , ... The U.S. Food ... requiring e-cigarette manufacturers to submit their products through an arduous federal approval process. ... products that entered the market since February 15, 2007. That would essentially ban ...
(Date:5/5/2016)... ... May 05, 2016 , ... TLC Laser Eye Centers ... California. The laser eye center will now be called “Gordon Schanzlin New Vision Institute, ... will remain at the full-service facility to ensure that patients continue to receive the ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... macroalgae can use ultraviolet light A (UV-A) for photosynthesis, researchers Juntian Xu and ... green, and brown seaweeds. The pair observed that when photosynthetically active radiation (i.e. ...
(Date:5/5/2016)... , ... May 05, 2016 , ... ... organization, announces McLaughlin & Smoak Benefits as the latest addition to its family ... has a dedicated team of compliance, wellness, human resources, and health care consumerism ...
Breaking Medicine News(10 mins):
(Date:5/4/2016)... May 4, 2016 BiondVax Pharmaceuticals Ltd. ... Ron Babecoff , will be attending the Joseph Gunnar ... . On Thursday, May 5, Dr. Babecoff will ... by Joseph Gunner & Co, taking place at ... that Dr. Babecoff will be using is downloadable from BiondVax,s ...
(Date:5/4/2016)... D.C. , May 4, 2016 ... member companies concluded a series of free workshops ... in global requirements for Good Distribution ... of quality assurance which ensures that products are consistently stored, ... the marketing authorization (MA) or product specification. Only a ...
(Date:5/4/2016)... 2016 Research and ... Acute Ischemic Stroke Market and Competitive Landscape ...      (Logo: http://photos.prnewswire.com/prnh/20160330/349511LOGO ... Stroke Market and Competitive Landscape Highlights 2016, ... pipeline products, Acute Ischemic Stroke epidemiology, Acute ...
Breaking Medicine Technology: